Where do we place pankomab in the reagents used to study the MUC1 superfamily?

Onkologie

Volumn 32, Issue 5, 2009, Pages 235-237

  Li, Jia ^a   Sullivan, Catherine A W ^a   Harris, Lyndsay ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; ESTROGEN RECEPTOR; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DF3; MONOCLONAL ANTIBODY PANKOMAB; MONOCLONAL ANTIBODY VU 4 H5; MUCIN 1; REAGENT; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; COMPARATIVE STUDY; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; OVARY CANCER; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL; HUMANS; INDICATORS AND REAGENTS; MUCIN-1; NEOPLASM PROTEINS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67549106789     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209989     Document Type: Editorial

References (17)

1. Duraisamy S, Kufe T, Ramasamy S, Kufe D: Evolution of the human MUC1 oncoprotein. Int J Oncol 2007;31(3):671-7.
2. Kufe DW: Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther 2008;7(1):81-4.
3. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005;65(22):10413-22.
4. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC: The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996;56(18):4244-9.
5. Shen Q, Rahn JJ, Zhang J, Gunasekera N, Sun X, Shaw AR, Hendzel MJ, Hoffman P, Bernier A, Hugh JC: MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res 2008;6(4):555-67.
6. Karsten U, Serttas N, Paulsen H, Danielczyk A, Goletz S: Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumorspecific epitope of the epithelial mucin (MUC1) Glycobiology 2004;14(8):681-92.
7. Danielczyk A, Stahn R, Faulstich D, Löffler A, Märten A, Karsten U, Goletz S: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55(11):1337-47.
8. Tarp MA, Clausen H: Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008;1780(3):546-63.
9. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J: Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996;65(5):664-70.
10. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P: Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14567-71.
11. Dian D, Wolfgang J, Kuhn C, Mayr D, Karsten U, Mylonas I, Friese K, Jeschke U: Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; and comparison with two established antibodies. Onkologie 2009;32: DOI: 10.1159/000209280.
12. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287-312.
13. Mommers EC, Page DL, Dupont WD, Schuyler P, Leonhart AM, Baak JP, Meijer CJ, van Diest PJ: Prognostic value of morphometry in patients with normal breast tissue or usual ductal hyperplasia of the breast. Int J Cancer 2001;95(5):282-5.
14. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91(11):1973-82.
15. Proceedings of the International Society for Oncodevelopmental Biology and Medicine (ISOBM) TD-4 International Workshop on Monoclonal Antibodies against MUC1. San Diego, California, November 17-23, 1996. Tumour Biol 1998;19 (Suppl 1):1-152.
16. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571-8.
17. Song EY, Qu CF, Rizvi SM, Raja C, Beretov J, Morgenstern A, Apostolidis C, Bruchertseifer F, Perkins A, Allen BJ: Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol Ther 2008;7(1):76-80.